Topic: Migraine

Migraine: Acute Therapies

Jan 2020 | Assessment

Interventions of Interest: ubrogepant (Ubrelvy™, Allergan) rimegepant (Nurtec™, Biohaven Pharmaceuticals)  lasmiditan (Reyvow™, Lilly) Migraine is a common cause of headache and is characterized by episodic, recurrent attacks that are classically pulsatile or throbbing, frequently involve one side of the head, and are associated with nausea and sensitivity to external stimuli such as light, sound, and smells. […]

Migraine: Acute & Chronic Therapies

Jun 2018 | Assessment

Interventions of interest: Erenumab (Aimovig®, Amgen/Novartis) Fremanezumab (Ajovy®, Teva) Galcanezumab (Emgality®, Eli Lilly) Migraine is a common, recurrent headache disorder and is among the top ten causes of years lived with disability in the US. Someone experiencing a migraine episode may feel moderate-to-severe pain and other symptoms (e.g., nausea, vomiting, or sensitivity to light or […]

Migraine: Acute & Chronic Therapies

Jul 2014 | Assessment

Interventions of interest, July 2014 review: OnabotulinumtoxinA (Botox®, Allergan, Inc) Transcutaneous electrical nerve stimulation (Cefaly®, Cefaly Technology) Single pulse transcranial magnetic stimulation (SpringTMS™, eNeura Inc.) Migraine is a common, recurrent headache disorder and is among the top ten causes of years lived with disability in the US. Someone experiencing a migraine episode may feel moderate-to-severe […]